Successful treatment of hepatitis C in sickle-cell disease.
Swaim
M W
MW
Agarwal
S
S
Rosse
W F
WF
D000328:Adult; D000755:Anemia, Sickle Cell / Q000150:complications*; D000986:Antisickling Agents / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006526:Hepatitis C / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D008875:Middle Aged; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use
D000986:Antisickling Agents; D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D012254:Ribavirin; D006918:Hydroxyurea